Yes, you are correct that I agree with you 100%. Then, the timeline for U.S. market resolution compresses materially. A Hikma loss would not be a narrow event; it would send shock waves through every generic quietly selling into the cardiovascular space under the assumption that enforcement risk was theoretical. Once one player is exposed through discovery-backed findings, others immediately reassess their own sales practices, records, and liability. Scrutiny follows fear. Pullbacks follow scrutiny. In that environment, the CV market does not “heal slowly” — it snaps back toward the party with clean hands, established labeling, and judicial validation. Under that scenario, restoration of Amarin’s U.S. CV franchise would not be gradual; it would be fast, defensive, and self-reinforcing. And that day is coming real soon!
Market Data 
Markets 
AI
